The BioPharm Brief: Oncology Momentum, CAR-T Advances, Strategic Expansion

Episode 1  ·  May 15, 08:59 PM
Headliner
Share
Subscribe

AstraZeneca reported encouraging bladder cancer data for Imfinzi plus BCG, Imviva shared early remission findings for allogeneic CAR-T therapy in lupus, and Biogen expanded its rare disease pipeline through its acquisition of Apellis Pharmaceuticals.

Share
Subscribe
Next
The BioPharm Brief: ADC Expansion, Early Breast Cancer, Biosimilar Momentum
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief